UBS raises Colgate-Palmolive stock price target on strong quarter By Investing.com

UBS raised its price target on Colgate-Palmolive to $100 from $98 and kept a Buy rating after a first-quarter 2026 beat, with EPS at $0.97 versus $0.94 expected and revenue of $5.32 billion versus $5.22 billion expected. Management held full-year guidance but now sees gross margin contraction instead of expansion because of higher raw material, packaging, and logistics inflation. The stock trades at $86.23, up nearly 12% year-to-date and still below its 52-week high of $99.33.

Analysis

This is less a simple defensive- staples rerating and more a signal that pricing power is still alive in pockets of consumer goods even as input-cost inflation re-accelerates. The second-order winner is actually the company’s emerging-market mix: when developed-market growth slows, branded staples with local execution can defend volume through smaller-ticket affordability and trade-down behavior, while weaker regional players with less scale get squeezed on freight, packaging, and working capital. If margin pressure is being absorbed without a guidance reset, that implies the market may be underestimating how much of the cost shock can be offset by mix, productivity, and selective pricing over the next 2-3 quarters.

The key risk is that this is a late-cycle earnings-quality story, not a clean multiple expansion story. Gross margin pressure from raw materials, packaging, and logistics tends to hit with a lag, so the near-term beat may mask a tougher back half if commodity and freight inflation persist. That means the stock can stay supported for weeks, but the setup becomes fragile into the next two earnings prints if volume growth decelerates or if peers start matching price increases and eroding category share.

Consensus looks to be focused on the dividend and the “better-than-feared” guide, but the more important signal is that large-cap staples are one of the few equity groups where pricing can still outrun cost inflation without immediate demand destruction. That makes the opportunity more about relative performance than absolute upside: the market may be overpaying for cyclicals that need a macro recovery, while underappreciating the durability of compounders with emerging-market leverage and balance-sheet flexibility. The contrarian concern is that if the inflation backdrop broadens, the valuation premium for defensives could compress even as fundamentals hold up.

Key Decisions for Investors

• Long CL on 1-3 month horizon on pullbacks into the low-$80s; risk/reward favors mid-single-digit upside toward prior highs if the next cost update does not deteriorate, with downside limited by dividend support and defensive demand.
• Pair trade: long CL / short a higher-multiple consumer staple with weaker pricing power for the next 1-2 quarters; express the view that scale and emerging-market mix should outperform firms more exposed to U.S. private-label pressure.
• Buy CL call spreads expiring after the next earnings print to capture a potential continued re-rate while capping premium outlay; thesis only works if management avoids another guide-down on margins.
• If raw material and logistics inflation data re-accelerate over the next 4-8 weeks, reduce exposure or hedge with sector ETF shorts because the market may have already priced in the first derivative of the beat but not the margin lag.